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ABSTRACT   Recently, the number of reports on skin manifestations, including tuberculids, 
developing as adverse reactions to the Bacille Calmette-Guérin (BCG) vaccine has increased 
in Japan. We encountered a case in which an infant developed cellulitis at the vaccination 
site. The patient was a girl who received the BCG vaccine 5 months after birth. Two months 
after vaccination, she developed a fever of 39ºC, and redness and swelling spread to the entire 
left upper arm. After being treated with oral cefditoren pivoxil, she was referred to our hospital 
and received treatment with intravenous sulbactam/ampicillin. Streptococcus pyogenes  was 
detected in a culture of the vaccination scars, and the reaction was very likely caused by 
pathogenic bacteria. There has been no previous report on a patient developing cellulitis 
following BCG vaccination caused by S. pyogenes at the vaccination site. Here, we describe 
such a case with a literature review. doi：10.11482/KMJ-E44(1)27　(Accepted on March 27, 2018)
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〈Case Report〉
INTRODUCTION
   The Bacille Calmette-Guérin (BCG) vaccine 
is  a  l ive vaccine containing an at tenuated 
Mycobacterium bovis  s t ra in  that  had been 
subcultured several times by Albert Calmette and 
Camille Guérin of the Pasteur Institute in France. 
The BCG vaccine used in Japan (Tokyo 172) is 
reported to have immunogenicity as high as that 
of vaccines used in other countries, but the strain 
is attenuated to considerably reduce the risk of 
adverse reactions１）. Furthermore, the percutaneous 
tube needle method, which is a vaccination method 
unique to Japan, is known to cause fewer local 
reactions compared to those caused by conventional 
intracutaneous vaccinations. 
   We encountered a case in which a 5-month-old 
infant received the BCG vaccination and developed 
cellulitis at the BCG vaccination site on the left 
upper arm 2 months later. Streptococcus pyogenes 
was isolated from the local lesion site. Reports 
of cellulitis as an adverse reaction following 
BCG vaccination are limited. As there has been 
no previous report of such a case caused by S. 
pyogenes, we herein report our case with a review 
of the relevant literature.
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CASE REPORT
   The patient was a 7-month-old girl who presented 
with fever, redness, swelling, and heat sensation 
spread to the entire left upper arm. She had received 
the BCG vaccination on the left upper arm on 
February 26, 20XX at 5 months of age. Around 
April 6, the patient presented to a different medical 
institution from the one where she received the 
vaccination because of redness and pustules at the 
BCG vaccination site. They were determined to 
be normal responses to the BCG vaccination, and 
her course was observed thereafter. However, she 
developed a fever of 39ºC and redness, swelling, 
and heat sensation in the entire left upper arm, so 
on April 30, she presented to the medical institution 
again. After being treated with oral cefditoren 
pivoxil, she was referred to our hospital for inpatient 
treatment on May 1.
   Other than the BCG vaccination, the patient＇s 
medical history was unremarkable. The patient 
had been delivered via spontaneous transvaginal 
delivery at 39 gestational weeks with a birth weight 
of 3,276 g. Neonatal asphyxia did not occur. The 
patient had received the following vaccines 3 times 
until 4 months of age, respectively: 13-valent 
pneumococcal conjugate vaccine; Haemophilus 
influenzae type b conjugate vaccine; and diphtheria, 
tetanus, pertussis and polio combined vaccine. There 
was no family history of primary immunodeficiency. 
The mother had complained of pharyngeal pain 1 
week prior to the onset of cellulitis in the child and 
was diagnosed with pharyngeal erythema at a local 
clinic, but details on medications are unknown.
Presentation on admission
   The patient＇s body temperature on admission was 
37.2ºC, pulse rate was 140 beats/min, blood pressure 
was 110/72 mmHg, and respiration rate was 28 
breaths/min. Laboratory data are presented in Table 
1. No pharyngeal erythema or cervical lymph node 
swelling was observed. The axillary lymph node 
was 1 cm in diameter and was mobile, elastic-hard, 
and tender to palpation. There was marked redness, 
swelling, and heat sensation over the entire left 
upper arm (Fig. 1) with mild redness at the BCG 
vaccination site. There were no abnormal findings 
in the chest or abdomen. 
Course after hospitalization
   The patient was diagnosed with cellulitis, and 
intravenous administration of sulbactam/ampicillin 
was initiated at a dose of 50 mg/kg, 3 times/day. 
Table 1. Laboratory ﬁndings on admission
Complete blood counts Biochemistry data Infection data
  White blood cells: 21,060/μl   Total protein: 6.8 g/dl   anti-streptolysin O antibody: <24 IU/ml
     Neutrophils: 44.0%   Albumin: 4.6 g/dl
     Lymphocytes: 46.0%   Total bilirubin: 0.9 mg/dl Immunoglobulin data
     Monocytes: 9.0%   Lactate dehydrogenase: 306 U/l   Immunoglobulin G: 305 mg/dl
     Eosinophils: 1.0%   Alkaline phosphatase: 503 U/l   Immunoglobulin A: 17 mg/dl
     Basophils: 0.0%   γ-glutamyl transpeptidase: 19U/l   Immunoglobulin M: 25 mg/dl
  Red blood cells: 4.82×106/μl   Aspartate aminotransferase: 44 U/l
  Hemoglobin: 11.9 g/dl   Alanine aminotransferase: 38 U/l Culture tests
  Hematocrit: 35.6%   Creatinine: 0.16 mg/dl   Blood: negative
  Platelets: 417,000/μl   Urea nitorogen: 6 mg/dl   Pus from BCG scars: S. pyogenes
  Uric acid: 3.5 mg/dl
Electrolyte data   Glucose: 118 mg/dl Urine test
  Sodium: 138 mEq/l   Total cholesterol: 181 mg/dl   Normal
  Potassium: 4.5 mEq/l   Creatine kinase: 131 U/l
  Chlorine: 104 mEq/l   C-reactive protein: 4.27 mg/dl
  Calcium: 10.6 mg/dl
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Fever was not observed thereafter, and the axillary 
lymph node swelling and inflammatory findings 
on the left upper arm improved rapidly (Fig. 2). 
As S. pyogenes was detected from a culture of the 
pus from the scars at the BCG vaccination site, it 
was assumed to be the causative agent. Laboratory 
findings improved to: white blood cell count, 9,660/
μL; and C-reactive protein level: 0.12 mg/dL on 
the 5th hospital day. Antimicrobial drug treatment 
was changed to oral administration of amoxicillin 
at 16 mg/kg 3 times/day for 5 consecutive days, 
and the patient was discharged from the hospital 
on the same day. The appearance of BCG site in 
convalescent phase (8 days after hospital discharge) 
is shown in Fig. 3.
DISCUSSION
   Following BCG vaccination, redness and swelling 
at the vaccination site are generally observed 
around the 10th day, with a peak within 4 – 6 
Fig. 1. Swelling and redness on the left upper arm on 
admission is shown. The red arrows indicate the BCG 
vaccination site.
Fig. 2. Rapid improvement of inﬂammatory ﬁndings on the 
left upper arm on the 5th hospital day is shown.
Fig. 3. The appearance of the BCG site 8 days after hospital 
discharge is shown.
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weeks, followed by scabbing for up to 2 months and 
cicatrization after up to  3 months１，２）. Deviations 
from this normal response include adverse reactions, 
such as axillary lymph node swelling, abscess at 
the local vaccination site, osteitis/osteomyelitis, 
systemic disseminated BCG infection, and cutaneous 
tuberculosis-like lesions (tuberculids)２－５）. 
Redness, swelling, and pimples a few days after 
BCG vaccination in children previously infected 
by tubercle bacillus (Koch＇s phenomenon)２） are 
usually not included as adverse reactions. When 
adverse reactions are suspected, it is important to 
conduct close examinations, including searching 
for a bacterium and observing the patient＇s course 
or providing treatment as required based on the 
time of vaccination, characteristics of eruption, and 
the patient＇s general condition. The patient in this 
case visited the medical institution for redness and 
pustules at the vaccination site as chief complaints 
1 month after vaccination, but they were determined 
to be normal responses to the BCG vaccination. 
As there is no detailed record from that time, we 
can only presume that they were, at the time, usual 
responses, because 1 month after vaccination is 
when the greatest response at the vaccination site is 
observed, and it took another month for the redness, 
swelling, and heat sensation to spread to the entire 
left upper arm. The scars at the BCG vaccination 
site could be a portal of entry of microorganisms. 
It is often difficult to distinguish between cellulitis 
and erysipelas, but we considered the skin lesion as 
cellulitis rather than erysipelas, because the lesion 
had an ambiguous boundary with the surrounding 
area.
   A few patients are annually reported to develop 
cellul i t is  as an adverse reaction following 
vaccination, including following the BCG vaccine, 
as seen in our present case６，７）. However, those 
cases are rarely reported in the literature, including 
cases reported abroad, and none of the published 
cases has involved the BCG vaccine. In Japan, the 
number of adverse reactions reported has increased 
on the whole since April 2005, when the BCG 
vaccine was injected directly into infants younger 
than 6 months without conducting a tuberculin 
skin test１，８）. Following this, the target age for 
vaccination has been changed to younger than 1 
year, and the standard period to receive vaccination 
has been newly set at 5 months to younger than 8 
months since April 2013. Regarding the adverse 
reactions following BCG vaccination, the frequency 
of regional lymphadenitis is high and is thus well 
known, but reports on osteitis/osteomyelitis and skin 
manifestations such as tuberculids have increased 
during the period that the vaccine was administered 
to infants younger than 5 months (Table 2). 
   Risk factors for cellulitis include varicella, 
atopic dermatitis, injury, burn, diabetes mellitus, 
primary immunodeficiency, and medication 
(immunosuppressants, steroids, and biological 
Table 2. Adverse reactions to the BCG vaccine and their frequencies (in 100,000 vaccinated people: comparison of 
the reported adverse reactions between 1994-2005 and 2006-2010) (aggregation in Japan)
 1994-2005 2006-2010
Total number 5.30 9.80
Axillary lymph node swelling (diameter ≥ 1 cm) 3.90 5.60
Abscess at the local vaccination site 0.55 0.68
Osteitis/osteomyelitis 0.07 0.40
Cutaneous tuberculosis-like lesion 0.41 2.30
Systemic disseminated BCG infection 0.02 0.12
Other abnormal reactions 0.43 0.66
     Lymph node swelling other than axilla 0.31 0.46
     Acute local response 0.05 0.10
     Others 0.07 0.10
From Reference 1) 
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preparations), but the present patient had neither 
medical history or signs to suspect primary 
immunodeficiency nor family history, although 
the patient＇s immunoglobulin G level was slightly 
lower than the normal range for an infant of her 
age. Furthermore, she had never used drugs with 
immunosuppressive action, nor did she have any 
dermatoses, such as atopic dermatitis.
   Streptococci account for approximately half of 
the causative agents of cellulitis and its frequency 
is as high as that of Staphylococcus aureus９－11）. 
Specifically, S. pyogenes should be considered 
as a causative pathogen for skin and soft tissue 
infections. Although there has been no report on 
cellulitis caused by this agent as an adverse reaction 
at the BCG vaccination site, it should be noted 
as a causative agent. As for the infection route, 
S. pyogenes may have been transmitted from the 
mother to the patient, as the mother had complained 
of pharyngeal pain 1 week prior to the onset of 
cellulitis in the child, but details are unknown. 
   We encountered a case in which cellulitis 
developed 2 months after BCG vaccination and 
spread from the vaccination site to the entire upper 
arm. S. pyogenes was assumed to be the causative 
agent. Thus, our case suggests that cellulitis caused 
by S. pyogenes should be noted as a potential 
adverse reaction following BCG vaccination.
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